Spider-web pain peptide (Nephilakinin-I)

What this is

Nephilakinin-I is a short ten-residue peptide discovered in the sticky capture web — not the venom gland — of the golden silk orb-weaver spider Nephila clavipes. It belongs to the bradykinin-related peptide family, a group of signaling peptides best known as pain and inflammation mediators in mammals. Volsi and colleagues (2006) isolated Nephilakinin-I alongside two sister peptides (Nephilakinin-II and -III) and bradykinin itself from aqueous washes of the web, suggesting these kinins may help immobilize captured prey on contact. The stored sequence GPNPGFSPFR represents the amino acid backbone; the active peptide carries a C-terminal amide cap (–NH₂) that is not visible in the one-letter sequence but is confirmed by the original ESI-MS/MS characterization.

History

Three novel bradykinin-related peptides — Nephilakinins I, II, and III — were first isolated and sequenced by Volsi and colleagues in a 2006 study published in Peptides. The team extracted them from the orb web of Nephila clavipes using gel permeation chromatography, then determined their primary sequences by electrospray ionization tandem mass spectrometry (ESI-MS/MS). The isolation was notable because the peptides came from the web itself rather than the spider's venom apparatus, implying that N. clavipes deposits bioactive kinins directly onto the sticky spiral threads as part of its prey-capture strategy. Bradykinin — the archetypal nine-residue kinin — was also recovered from the same web extracts, confirming that the spider incorporates endogenous kinin-family chemistry into the capture web (Volsi and colleagues, 2006).

What it does

Nephilakinin-I behaves as a bradykinin B2 receptor agonist in smooth muscle bioassays. Volsi and colleagues (2006) demonstrated that it causes contraction of isolated rat ileum and relaxation of rat duodenum, the two classical tissue-level signatures of B2 receptor activation. Both effects were produced at quantities greater than what bradykinin itself required, indicating that Nephilakinin-I is a weaker B2 agonist than the parent nonapeptide. The biological rationale in the capture-web context is prey immobilization: kinins applied topically through web contact could disrupt the neuromuscular physiology of insects or other small invertebrates that land on the web. The platform additionally annotates GALR1 (galanin receptor type 1) as a target, reflecting structural overlap between the C-terminal bradykinin-fragment scaffold used in GALR1-selective research ligands and the Nephilakinin-I sequence; direct binding measurements of Nephilakinin-I at GALR1 have not been published.

Evidence

• Human: No human studies. Nephilakinin-I is a research peptide with no clinical development.
• Animal: Rat ileum (constriction) and rat duodenum (relaxation) bioassays confirmed B2-type agonist activity, with potency lower than bradykinin (Volsi and colleagues, 2006).
• In vitro: Peptide identity and sequence confirmed by ESI-MS/MS; isolated from aqueous extracts of Nephila clavipes capture web (Volsi and colleagues, 2006). No registered trials on ClinicalTrials.gov for Nephilakinin-I or Nephilakinin.

Mechanism

Galanin receptor type 1 (GALR1) is a class A GPCR coupled to Gi/Go proteins. Activation reduces intracellular cAMP by inhibiting adenylyl cyclase, and opens G protein-gated inwardly rectifying potassium (GIRK) channels, hyperpolarizing neurons (Wang and colleagues, 1997; Webling and colleagues, 2012). GALR1 is expressed in the hippocampus, hypothalamus, amygdala, spinal cord, and dorsal root ganglia, where it modulates neuronal excitability, suppresses seizure activity, and attenuates nociceptive signaling (Webling and colleagues, 2012). The bradykinin receptor pathway by which Nephilakinin-I is directly characterized operates through a separate GPCR class: B2 receptor activation typically couples to Gq/11, stimulating phospholipase C and elevating intracellular calcium in smooth muscle. The relationship between Nephilakinin-I's C-terminal sequence (–GPGFSPFR) and the bradykinin fragment used in GALR1-selective chimeric ligands (such as galanin(1–13)–bradykinin(2–9)amide) makes GALR1 a plausible pharmacological neighbor, but published receptor-binding data for Nephilakinin-I at GALR1 are not available.

Open questions

• Does Nephilakinin-I bind GALR1 directly, and if so, with what affinity and functional outcome?
• What is the selectivity of Nephilakinin-I for bradykinin B2 versus B1 receptors?
• Do all three Nephilakinin variants (I, II, III) show equivalent B2 potency, or does the divergent N-terminal sequence alter receptor interaction?
• What is the ecological function of kinin deposition in orb-weaver capture webs — is it primarily insecticidal, paralytic, or digestive?
• Has Nephilakinin-I been tested in insect nervous system preparations, where kinin cholinergic blocking activity has been described for other arthropod kinins?

Related peptides

• Bradykinin — the archetypal nine-residue kinin (RPPGFSPFR) from which Nephilakinin-I differs at the N-terminal extension; the founding pharmacological reference for the B2 receptor class.
• Nephilakinin-II (EAPPGFSPFR) and Nephilakinin-III (PSPPGFSPFR) — sister peptides co-isolated from the same Nephila clavipes web extracts by Volsi and colleagues (2006), sharing the conserved –GPFSPFR C-terminus.